GPC3-Binding CAR T Cells for Tumor Immune Evasion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current T cell therapies face challenges in effectively targeting and killing cancer cells, particularly those expressing glypican 3 (GPC3), such as hepatocellular carcinoma cells, due to mechanisms employed by cancer cells to evade immune cells.
Innovation Solution
Development of antibodies and chimeric antigen receptors (CARs) with specific GPC3 binding domains, comprising defined complementarity determining regions (CDRs) and variable domains, engineered into T cells or NK cells to enhance their ability to target and kill GPC3-expressing cancer cells, along with the use of dominant negative TGFβ receptors to modulate immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional T cell therapies are used to target cancer cells, then the immune system can recognize cancer cells, but cancer cells employ mechanisms to evade immune cell targeting
Solution Approach 1:
The T cell receptor is segmented into distinct functional domains: a binding domain (antibody or TCR) that recognizes GPC3, a spacer region, and a signaling domain (CD3ζ or FcRγ). This segmentation allows independent optimization of binding specificity and signaling capability, enabling effective targeting despite cancer evasion mechanisms.
Solution Approach 2:
The patent introduces intermediary molecules including costimulatory molecules (CD28, CD137, CD40) and cytokines (IL-2, IL-15, IL-21) that mediate between the GPC3 binding domain and the T cell's intracellular signaling machinery. These intermediaries amplify the binding signal and overcome cancer cell evasion by providing additional activation pathways.
2Reliability
If T cells are engineered to express CARs or TCRs targeting GPC3, then specific cancer cell targeting is achieved, but the complexity of the therapeutic construct increases
Solution Approach 1:
The CAR/TCR construct is designed to perform multiple functions simultaneously: GPC3 recognition, signal transduction, costimulation (via molecules like CD28 and CD137), and cytokine production (IL-2, IL-15, IL-21). This multi-functionality is achieved through modular domain assembly, reducing the need for separate therapeutic components and simplifying the overall construct.
Solution Approach 2:
The patent employs a nested domain architecture where the binding domain is embedded within a larger CAR/TCR structure that contains integrated costimulatory and signaling domains. The spacers and linkers are nested within the overall protein fold, creating a compact, multi-functional receptor complex that minimizes structural complexity.
3Productivity
If immune cells are enhanced to target GPC3-expressing cells, then cancer cell destruction is improved, but the immune response may be modulated by dominant negative TGFβ receptors
Solution Approach 1:
The patent converts the potentially harmful effect of TGFβ-mediated immune suppression into a benefit by using dominant negative TGFβ receptors. These receptors bind TGFβ ligands but cannot activate the downstream signaling pathway, thereby blocking suppressive effects and enhancing immune cell activity against GPC3-expressing cancer cells.
Solution Approach 2:
The patent modifies the TGFβ signaling pathway by introducing dominant negative receptors that change the functional state of the pathway from suppressive to activating. This parameter change in the immune response environment enhances cancer cell destruction efficiency while controlling adaptability through targeted modulation rather than complete immune system reconfiguration.
Data Source
AI summary
Provided are antibodies, fragments thereof, chimeric antigen receptors (CARs) and T cell receptors (TCRs) comprising one or more of the GPC3 binding domains disclosed herein. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.